Barry D. Lebowitz

Barry D. Lebowitz

Auto-generated profile, based on publicly available information

Barry D. Lebowitz

Department of Psychiatry, University of California, San Diego, CA

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
TST. Scott Stroup
T. Scott Stroup
JMJoseph P. McEvoy
Joseph P. McEvoy
MSMarvin S. Swartz
Marvin S. Swartz
RRRobert A. Rosenheck
Robert A. Rosenheck
JHJohn K. Hsiao
John K. Hsiao
The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.

1 January 2006 in American Journal of Psychiatry
Verified
Journal Article
Closed access
MTMadhukar Trivedi
Madhukar Trivedi
ARA. John Rush
A. John Rush
SWStephen R. Wisniewski
Stephen R. Wisniewski
ANAndrew A. Nierenberg
Andrew A. Nierenberg
DWDiane Warden
Diane Warden
STSTAR*D Study Team
STAR*D Study Team

12 October 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LSLon S. Schneider
Lon S. Schneider
PTPierre N. Tariot
Pierre N. Tariot
KDKaren S. Dagerman
Karen S. Dagerman
SDSonia M. Davis
Sonia M. Davis
JHJohn K. Hsiao
John K. Hsiao
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.

1 February 2004 in Controlled Clinical Trials
Verified
Journal Article
Closed access
ARA.John Rush
A.John Rush
MFMaurizio Fava
Maurizio Fava
SWStephen R Wisniewski
Stephen R Wisniewski
PLPhilip W Lavori
Philip W Lavori
MTMadhukar H Trivedi
Madhukar H Trivedi
FGfor the STAR*D Investigators Group
for the STAR*D Investigators Group

23 March 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MTMadhukar Trivedi
Madhukar Trivedi
MFMaurizio Fava
Maurizio Fava
SWStephen R. Wisniewski
Stephen R. Wisniewski
MTMichael E. Thase
Michael E. Thase
FQFrederick Quitkin
Frederick Quitkin
ARA. John Rush
A. John Rush
Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach. We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation. The primary outcome of remission of symptoms was defined as a score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of this study; scores were obtained over the telephone by raters blinded to treatment assignment. The 16-item Quick Inventory of Depressive Symptomatology — Self-Report (QIDS-SR-16) was used to determine the secondary outcomes of remission (defined as a score of less than 6 at the end of this study) and response (a reduction in baseline scores of 50 percent or more). The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent). Sustained-release bupropion, however, was associated with a greater reduction (from baseline to the end of this study) in QIDS-SR-16 scores than was buspirone (25.3 percent vs. 17.1 percent, P<0.04), a lower QIDS-SR-16 score at the end of this study (8.0 vs. 9.1, P<0.02), and a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P<0.009). Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings. Augmentation with sustained-release bupropion does have certain advantages, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events. (ClinicalTrials.gov number, NCT00021528.)

31 January 2011 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
MSM. Katherine Shear
M. Katherine Shear
NSNaomi Simon
Naomi Simon
MWMelanie Wall
Melanie Wall
SZSidney Zisook
Sidney Zisook
RNRobert Neimeyer
Robert Neimeyer
AKAparna Keshaviah
Aparna Keshaviah
Bereavement is a severe stressor that typically incites painful and debilitating symptoms of acute grief that commonly progresses to restoration of a satisfactory, if changed, life. Normally, grief does not need clinical intervention. However, sometimes acute grief can gain a foothold and become a chronic debilitating condition called complicated grief. Moreover, the stress caused by bereavement, like other stressors, can increase the likelihood of onset or worsening of other physical or mental disorders. Hence, some bereaved people need to be diagnosed and treated. A clinician evaluating a bereaved person is at risk for both over‐and under‐diagnosis, either pathologizing a normal condition or neglecting to treat an impairing disorder. The authors of DSM IV focused primarily on the problem of over‐diagnosis, and omitted complicated grief because of insufficient evidence. We revisit bereavement considerations in light of new research findings. This article focuses primarily on a discussion of possible inclusion of a new diagnosis and dimensional assessment of complicated grief. We also discuss modifications in the bereavement V code and refinement of bereavement exclusions in major depression and other disorders. Depression and Anxiety, 2011.